Back to mobile site

Neurocrine Bio. (NBIX) PT Raised to $182 at Goldman Sachs

December 16, 2024 6:48 AM EST Send to a Friend
Goldman Sachs analyst Chris Shibutani raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $182.00 (from $177.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login